| Literature DB >> 34233618 |
Xiao-Qin Li1, Chun Yin1, Xiao-Li Li1, Wen-Li Wu1, Kun Cui2.
Abstract
BACKGROUND: Previous studies have validated the capability of SYNTAX score (SS) and clinical SYNTAX score (CSS) in the prediction of clinical outcomes in patients who have undergone PCI; however, studies on comparison of these two scoring systems in Chinese population have been sparse.Entities:
Keywords: Clinical SYNTAX score; Clinical outcomes; Percutaneous coronary intervention; SYNTAX score
Year: 2021 PMID: 34233618 PMCID: PMC8265139 DOI: 10.1186/s12872-021-02144-w
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Baseline clinical characteristics and risk factors
| Variable | SSlow ≤ 8 (177) | 8 < SSmid < 18 (177) | 18 ≤ SShigh (193) | Total | |
|---|---|---|---|---|---|
| Baseline characteristics | |||||
| Male sex | 108 (61.0%) | 123 (69.5%) | 142 (73.6%) | 373 (68.2%) | 0.031 |
| Age (years) | 65.11 ± 4.00 | 68.20 ± 8.19 | 66.92 ± 3.00 | 66.82 ± 3.50 | 0.045 |
| Body mass index (kg/m2) | 24.26 ± 3.07 | 23.52 ± 2.98 | 23.97 ± 3.12 | 23.67 ± 2.12 | 0.211 |
| Risk factors | |||||
| Left ventricular ejection fraction | 67.17 ± 10.38 | 69.74 ± 8.66 | 65.71 ± 9.68 | 67.71 ± 7.63 | < 0.001 |
| Creatinine clearance, ml/1.73 m2 | 64.41 ± 37.32 | 57.41 ± 25.14 | 56.53 ± 26.87 | 58.53 ± 16.65 | 0.06 |
| Creatinine > 100 μmol/l | 33 (18.6%) | 44 (24.9%) | 66 (34.2%) | 144 (26.3) | 0.003 |
| Hypertension | 125 (70.6%) | 116 (65.5%) | 127 (65.8%) | 370 (67.6%) | 0.513 |
| Diabetes mellitus | 48 (27.1%) | 59 (33.3%) | 52 (26.9%) | 159 (29.1%) | 0.315 |
| Hypercholesterolemia | 67 (37.9%) | 73 (41.2%) | 82 (42.5%) | 222 (40.6%) | 0.648 |
| Current smoker | 71 (40.1%) | 60 (33.9%) | 89 (46.1%) | 220 (40.2%) | 0.057 |
| Stroke | 24 (13.6%) | 13 (7.3%) | 20 (10.4%) | 57 (10.4%) | 0.16 |
| Chronic pulmonary disease | 17 (9.6%) | 21 (11.9%) | 24 (12.4%) | 62 (11.3%) | 0.667 |
| Previous MI | 9 (5.1%) | 15 (8.5%) | 8 (4.1%) | 32 (5.9%) | 0.181 |
| Previous PCI | 6 (3.4%) | 11 (6.2%) | 3 (2.6%) | 20 (3.6%) | 0.182 |
| SS | 4.81 ± 2.21 | 12.86 ± 2.66 | 26.07 ± 6.83 | 14.90 ± 8.83 | < 0.0001 |
| Indication for treatment | |||||
| Stable angina | 60 (33.9%) | 76 (42.9%) | 69 (35.8%) | 205 (37.4%) | 0.177 |
| Unstable angina | 53 (29.9%) | 41 (23.2%) | 57 (29.5%) | 151 (27.6%) | 0.174 |
| ST-segment elevation MI | 27 (15.3%) | 26 (14.7%) | 34 (17.6%) | 87 (15.9%) | 0.714 |
| Non-ST-segment elevation MI | 15 (8.5%) | 14 (7.9%) | 7 (3.6%) | 36 (6.6%) | 0.118 |
| Silent ischemia | 22 (12.4%) | 19 (10.7%) | 27 (14.0%) | 27 (12.4%) | 0.638 |
| Medication at discharge | |||||
| Aspirin | 144 (81.4%) | 141 (80.1%) | 172 (89.1%) | 457 (83.5%) | 0.038 |
| Clopidogrel | 139 (78.5%) | 149 (84.2%) | 164 (85.0%) | 452 (82.6%) | 0.211 |
| β-Blocker | 88 (49.7%) | 93 (52.5%) | 90 (46.6%) | 90 (49.5%) | 0.524 |
| Statin | 139 (78.5%) | 146 (82.5%) | 165 (85.5%) | 271 (85.5%) | 0.215 |
| ACEI/ARB | 82 (46.3%) | 92 (52.0%) | 82 (42.5%) | 256 (46.8%) | 0.186 |
Value are n (%), mean ± SD
MI myocardial infarction, PCI percutaneous coronary intervention, SS SYNTAX score, SYNTAX Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker
Fig. 1Distribution of SS and CSS among the 547 patients enrolled in the study. Histograms of the SS (left side) and CSS (right side) with a superimposed normal curve. Both score distributions are skewed to right, and not normally distributed. Mean ± SD values and median values plus inter-quartile range (IQR) are reported
Angiographic and procedural characteristics stratified according to SS tertile
| Variable | SSlow ≤ 8 (177) | 8 < SSmid < 18 (177) | 18 ≤ SShigh (193) | Total | |
|---|---|---|---|---|---|
| Diseased lesions | |||||
| Number of disease lesions | 1.5 ± 0.7 | 2.1 ± 1.0 | 3.3 ± 1.3 | 2.3 ± 1.6 | < 0.001 |
| 1-Vessel disease | 131 (74.0%) | 46 (26.0%) | 5 (2.6%) | 182 (33.3%) | < 0.001 |
| 2-Vessel disease | 40 (22.6%) | 86 (48.6%) | 59 (30.6%) | 185 (33.8%) | < 0.001 |
| 3-Vessel disease | 6 (3.4%) | 45 (25.4%) | 129 (66.8%) | 180 (32.9%) | < 0.001 |
| Lesion location | |||||
| Left main stem | 0 (0.0%) | 3 (1.7%) | 33 (17.1%) | 36 (6.6%) | < 0.001 |
| Left anterior artery | 95 (53.7%) | 162 (91.5%) | 185 (95.9%) | 442 (80.8%) | < 0.001 |
| Circumflex artery | 53 (29.9%) | 81 (45.8%) | 150 (77.7%) | 284 (51.9%) | < 0.001 |
| Right artery | 81 (45.8%) | 107 (60.5%) | 157 (81.3%) | 345 (63.1%) | < 0.001 |
| Lesion characteristics | |||||
| Bifurcated lesion | 31 (17.5%) | 99 (55.9%) | 150 (77.7%) | 280 (51.2%) | < 0.001 |
| Trifurcated lesion | 0 (0.0%) | 4 (2.3%) | 17 (8.8%) | 21 (3.8%) | < 0.001 |
| Ostial lesion | 8 (4.5%) | 6 (3.4%) | 10 (5.2%) | 24 (4.4%) | 0.669 |
| Lesion > 20 mm | 11 (6.2%) | 48 (27.1%) | 108 (56.0%) | 167 (30.5%) | < 0.0001 |
| Lesion with thrombus | 1 (0.6%) | 1 (0.6%) | 7 (3.6%) | 9 (1.6%) | < 0.0001 |
| Calcified lesion | 3 (1.7%) | 19 (10.7%) | 53 (27.5%) | 75 (13.7%) | < 0.0001 |
| Total occlusion | 1 (0.6%) | 14 (7.9%) | 64 (33.2%) | 79 (14.4%) | < 0.0001 |
| Chronic total occlusion | 0 (0.0%) | 3 (1.7%) | 34 (17.6%) | 37 (6.8%) | < 0.0001 |
| Treated coronary | |||||
| 3-Vessel intervention | 1 (0.6%) | 14 (7.9%) | 39 (20.2%) | 54 (9.9%) | < 0.0001 |
| Left main stem | 0 (0.0%) | 2 (1.1%) | 0 (0.0%) | 2 (0.4%) | < 0.0001 |
| Left anterior descending | 84 (47.5%) | 125 (70.6%) | 91 (47.2%) | 300 (54.8%) | < 0.0001 |
| Circumflex | 41 (23.2%) | 34 (19.2%) | 43 (22.3%) | 118 (21.6%) | 0.636 |
| Right | 68 (38.4%) | 70 (39.5%) | 84 (43.5%) | 222 (40.6%) | 0.573 |
| Procedural characteristics | |||||
| Number of implanted stents | 1.6 ± 0.9 | 2.1 ± 1.0 | 3.0 ± 1.3 | 2.2 ± 1.5 | < 0.0001 |
| Total stent length/patient (mm) | 29.3 ± 16.8 | 41.1 ± 28.0 | 64.3 ± 30.7 | 66.3 ± 32.5 | < 0.0001 |
| Maximal pressure of stent deployment | 13.8 ± 2.6 | 13.0 ± 2.8 | 14.8 ± 2.7 | 13.8 ± 1.7 | < 0.0001 |
| Patients with complete revascularization | 147 (83.1%) | 91 (51.4%) | 25 (13%) | 263 (48.1%) | < 0.0001 |
| Use of glycoprotein IIb/IIIa inhibitors | 0 (0.0%) | 5 (2.8%) | 16 (8.3%) | 21 (4.8%) | < 0.0001 |
| Post-procedural hospital stay, days | 10.0 ± 5.9 | 9.6 ± 5.0 | 12.4 ± 9.6 | 10.6 ± 4.6 | 0.001 |
| Intravascular imaging | 0 (0.0%) | 1 (0.2%) | 7 (1.3%) | 8 (1.5%) | < 0.0001 |
Value are n (%), mean ± SD
SS SYNTAX score
Clinical outcomes 2 years since date of procedural according to SS
| Variable | SSlow ≤ 8 (177) | 8 < SSmid < 18 (177) | 18 ≤ SShigh (193) | |
|---|---|---|---|---|
| MACCE** | 0 (0%) | 12 (6.8%) | 26 (13.5%) | < 0.0001 |
| All-cause death | 3 (1.7%) | 6 (3.4%) | 8 (4.1%) | 0.385 |
| Target vessel failure# | 0 (0%) | 4 (2.3%) | 11 (5.7%) | 0.003 |
| Any repeat revascularization | 0 (0%) | 7 (4.0%) | 14 (7.3%) | 0.001 |
| Stroke | 0 (0%) | 3 (1.7%) | 0 (0%) | 0.045 |
| ARC stent thrombosis* | 0 (0%) | 1 (0.6%) | 4 (2.1%) | 0.094 |
| Hospitalization due to angina pectoris | 17 (9.6%) | 17 (9.6%) | 30 (15.6%) | 0.113 |
| Cardiac death | 0 (0%) | 3 (1.7%) | 8 (4.2%) | 0.016 |
Values are n (%), mean ± SD
ACS acute coronary syndrome
*Defined according to the Academic Research Consortium (ARC)
#Target lesion failure: cardiac death, target-vessel driven myocardium infraction, ischemia-driven target lesion revascularization (TLR)
**MACCE: cardiac death, any MI, any repeat revascularization and stroke
Clinical outcomes 2 years since date of procedural according to CSS
| Variable | CSSLOW (180) | CSSMID (185) | CSSHIGH (182) | |
|---|---|---|---|---|
| MACCE** | 3 (1.7%) | 7 (3.8%) | 28 (15.4%) | < 0.0001 |
| All-cause death | 1 (0.6%) | 4 (2.2%) | 12 (6.6%) | 0.003 |
| Target vessel failure# | 0 (0%) | 4 (2.2%) | 11 (6.0%) | 0.002 |
| Any repeat revascularization | 3 (1.7%) | 4 (2.2%) | 14 (7.7%) | 0.004 |
| Stroke | 0 (0%) | 1 (0.5%) | 2 (1.1%) | 0.367 |
| ARC stent thrombosis* | 0 (0%) | 4 (2.2%) | 1 (0.5%) | 0.078 |
| Hospitalization due to angina pectoris | 19 (10.6%) | 25 (13.8%) | 64 (11.7%) | 0.563 |
| Cardiac death | 0 (0%) | 1 (0.5%) | 10 (5.5%) | < 0.0001 |
Values are n (%), mean ± SD
*Defined according to the Academic Research Consortium (ARC)
#Target lesion failure: cardiac death, target-vessel driven myocardium infraction, ischemia-driven target lesion revascularization (TLR)
**MACCE: cardiac death, any MI any repeat revascularization and stroke
Fig. 2Clinical outcomes at 2-year follow up stratified by SS (A) and CSS (B) tertile. Kaplan–Meier curves are presented for major adverse cardiac and cerebral events, target lesion failure, all-cause death and cardiac death/myocardial infarction
Fig. 3Receiver operating characteristic (ROC) curves for SS and CSS. (A) major adverse cardiac and cerebral events (B) target lesion failure (C) all-cause death (D) cardiac death/myocardium infarction. AUC area-under-the-curve, CI confidence interval, SS SYNTAX score, CSS clinical SYNTAX score
COX multivariable analysis
| Clinical outcome | Hazard ratio for CSS (95% CI) | Hazard ratio for SS (95% CI)* | ||
|---|---|---|---|---|
| All-cause death | 1.012 (1.000–1.024) | 0.049 | 1.049 (1.005–1.095) | 0.027 |
| Target lesion failure | 1.014 (1.001–1.028) | 0.034 | 1.090 (1.042–1.140) | < 0.0001 |
| Cardiac death/MI | 1.018 (1.004–1.030) | 0.006 | 1.100 (1.049–1.153) | < 0.0001 |
| MACCE | 1.017 (1.009–1.022) | < 0.0001 | 1.101 (1.070–1.134) | < 0.0001 |
| Any MI | 1.024 (1.002–1.047) | 0.034 | 1.105 (1.010–1.209) | 0.03 |
| Any repeat revascularization | 1.018 (1.008–1.029) | < 0.0001 | 1.107 (1.064–1.152) | < 0.0001 |
CI confidence interval, HR hazard ratio, ACS acute coronary syndrome, MACCE major adverse cardiac and cerebral events, SS SYNTAX score, CSS clinical SYNTAX score
MACCE reclassification into CSS tertile
| CSSLOW | CSSMID | CSSHIGH | Total | |
|---|---|---|---|---|
| Patients with MACCE events | ||||
| SSLOW | 0 | 0 | 0 | 0 |
| SSMID | 2 | 0 | 4 | 6 |
| SSHIGH | 0 | 4 | 0 | 4 |
| Total | 2 | 4 | 4 | 10 |
| Patients without MACCE events | ||||
| SSLOW | 149 | 25 | 3 | 178 |
| SSMID | 29 | 92 | 49 | 160 |
| SSHIGH | 0 | 63 | 126 | 189 |
| Total | 178 | 181 | 178 | 537 |
Fig. 4Reclassification of patients from SS tertiles to CSS tertiles